In october 20909 Sanofi-Aventis and Micromet signed an agreement to license and develop the cancer treatment BiTE antibody. According to the agreement, Micromet will develop the treatment through Phase I trials and Sanofi will then take charge of further development and commercialisation of the antibody. Sanofi is to pay Microment €8 million upfront, and Micromet could then receive up to €162 million in royalties and up to an additional €150 million for sales.
Advertisement
